Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert
    X

    Find Clinical Drug Pipeline Developments & Deals by Daiichi Sankyo Co Ltd

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Therapeutic Area filter
      Study Phase filter
        Country filter
          News Type filter
            Company filter
              refresh

              Companies By Therapeutic Area Full Screen

              Development Status Full Screen

              Daiichi Sankyo Co Ltd

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              Daiichi Sankyo & Gustave Roussy collaborate for oncology research

              Contact the Supplier

              Lead Product(s): DS-1062

              Therapeutic Area: Oncology Product Name: DS-1062

              Highest Development Status: Phase II Product Type: Large molecule

              Recipient: Gustave Roussy

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration July 22, 2020

              Details:

              The collaboration focuses on clinical and translational research, including potential combination strategies for DS-1062, in patients with advanced non-small cell lung cancer, and for patritumab deruxtecan, in patients with metastatic breast cancer.

              Daiichi Sankyo Co Ltd

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients

              Contact the Supplier

              Lead Product(s): Prasugrel Hydrochloride

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Effient

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 21, 2020

              Details:

              The study was carried out in a double-blind comparative manner to examine the efficacy and safety of prasugrel and clopidogrel in 234 thrombotic stroke patients with one or more risk factors for the recurrence of ischemic stroke.

              Daiichi Sankyo Co Ltd

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              Daiichi Sankyo Announces Participation in AMR Action Fund

              Contact the Supplier

              Lead Product(s): Antimicrobial Resistance Antibiotics

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $20.0 million Upfront Cash: Undisclosed

              Deal Type: Funding July 10, 2020

              Details:

              The AMR Action Fund, established to promote the development of new antimicrobial agents for AMR, provides technical assistance and invests about 1 billion US dollars for small biotechnology companies to bring 2 to 4 new antibiotics to patients by 2030.

              Daiichi Sankyo Co Ltd

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer

              Contact the Supplier

              Lead Product(s): Trastuzumab Deruxtecan

              Therapeutic Area: Oncology Product Name: DS-8201

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 06, 2020

              Details:

              The MAA is based on the positive results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan monotherapy in patients with HER2 positive metastatic breast cancer who had received two or more prior anti-HER2 regimens.

              Daiichi Sankyo Co Ltd

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer

              Contact the Supplier

              Lead Product(s): DS-1062

              Therapeutic Area: Oncology Product Name: DS-1062

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 01, 2020

              Details:

              Phase 1 study now evaluating DS-1062, a TROP2 directed DXd ADC, in patients with advanced/ unresectable or metastatic triple negative breast cancer.

              Daiichi Sankyo Co Ltd

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              Daiichi Sankyo Provides Update on CHMP Review of Pexidartinib, a CSF1R Inhibitor for the Treatment of Patients with TGCT

              Contact the Supplier

              Lead Product(s): Pexidartinib

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 26, 2020

              Details:

              CHMP of the European Medicines Agency has adopted a negative opinion on the Marketing Authorization Application For pexidartinib for the treatment of a subset of adult patients with severe tenosynovial giant cell tumor (TGCT).

              Daiichi Sankyo Co Ltd

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              Daiichi Sankyo Announces Decision to Develop Vaccine in Japan for Novel Corona Virus Infection (COVID-19)

              Contact the Supplier

              Lead Product(s): mRNA vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 12, 2020

              Details:

              Daiichi Sankyo is set to develop a mRNA vaccine candidate to protect against Covid-19 infection in the country. The project, Fundamental Research on the Control of a Novel Coronavirus (2019-nCoV), is supported by the Japan Agency for Medical Research and Development (AMED).

              Daiichi Sankyo Co Ltd

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              The University of Tokyo, RIKEN, Nichi-Iko & Daiichi Sankyo Ink Collaborative R&D on Nafamostat Inhalation Formulation to Treat COVID-19

              Contact the Supplier

              Lead Product(s): Nafamostat

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: The University of Tokyo

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration June 08, 2020

              Details:

              Through the partnership, The University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo have reached a basic agreement on collaborative R&D on a Nafamostat inhalation formulation for the treatment of novel corona virus infection (COVID-19).

              Daiichi Sankyo Co Ltd

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA in Lung Cancer

              Contact the Supplier

              Lead Product(s): DS-1062,Pembrolizumab

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Merck & Co. Inc.

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 29, 2020

              Details:

              Strategic research collaboration aims at to evaluating the combination of DS-1062, a TROP2 directed DXd antibody drug conjugate, and KEYTRUDA in patients with previously-treated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.

              Daiichi Sankyo Co Ltd

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              JAPAN Japan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              Daiichi Sankyo and Syneos Health® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC Oncology Pipeline

              Contact the Supplier

              Lead Product(s): Trastuzumab Deruxtecan

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Recipient: Syneos Health

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 28, 2020

              Details:

              Under the agreement, Syneos Health will provide both strategic and operational solutions for three lead Daiichi Sankyo DXd antibody drug conjugates (ADC): DS-1062, U3-1402 and DS-8201 (known as ENHERTU®).

              PharmaCompass

              PharmaCompass__DigitalAd